Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Alba Di Pardo, Salvatore Castaldo, Enrico Amico, Giuseppe Pepe, Federico Marracino, Luca Capocci, Alfredo Giovannelli, Michele Madonna, Jeroen van Bergeijk, Fabio Buttari, Elizabeth van der Kam, Vittorio Maglione

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approachesmay open the door to newandmore targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulating sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2mice, a widely used HD animalmodel. Chronic administration of low-dose (0.1mg/kg) A-971432 slowed down the progression of the disease and significantly prolonged lifespan in symptomatic R6/2mice. Such beneficial effects were associated with activation of pro-survival pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood-brain barrier (BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432 completely protected HDmice fromthe classic progressivemotor deficit and preserved BBB integrity. Beside representing a promising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P receptor 5may be also seen as an effective approach to target brain vasculature defects in the disease.

Original languageEnglish
Pages (from-to)2490-2501
Number of pages12
JournalHuman Molecular Genetics
Volume27
Issue number14
DOIs
Publication statusPublished - Jul 15 2018

Fingerprint

Huntington Disease
Therapeutic Uses
Blood-Brain Barrier
Lysosphingolipid Receptors
Animal Models
Sphingolipids
Brain-Derived Neurotrophic Factor
Neurodegenerative Diseases
Disease Progression
Homeostasis
Therapeutics
Brain

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease. / Di Pardo, Alba; Castaldo, Salvatore; Amico, Enrico; Pepe, Giuseppe; Marracino, Federico; Capocci, Luca; Giovannelli, Alfredo; Madonna, Michele; van Bergeijk, Jeroen; Buttari, Fabio; van der Kam, Elizabeth; Maglione, Vittorio.

In: Human Molecular Genetics, Vol. 27, No. 14, 15.07.2018, p. 2490-2501.

Research output: Contribution to journalArticle

Di Pardo, Alba ; Castaldo, Salvatore ; Amico, Enrico ; Pepe, Giuseppe ; Marracino, Federico ; Capocci, Luca ; Giovannelli, Alfredo ; Madonna, Michele ; van Bergeijk, Jeroen ; Buttari, Fabio ; van der Kam, Elizabeth ; Maglione, Vittorio. / Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease. In: Human Molecular Genetics. 2018 ; Vol. 27, No. 14. pp. 2490-2501.
@article{ec3debf1f8c349f7ad098074da39989c,
title = "Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease",
abstract = "Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approachesmay open the door to newandmore targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulating sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2mice, a widely used HD animalmodel. Chronic administration of low-dose (0.1mg/kg) A-971432 slowed down the progression of the disease and significantly prolonged lifespan in symptomatic R6/2mice. Such beneficial effects were associated with activation of pro-survival pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood-brain barrier (BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432 completely protected HDmice fromthe classic progressivemotor deficit and preserved BBB integrity. Beside representing a promising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P receptor 5may be also seen as an effective approach to target brain vasculature defects in the disease.",
author = "{Di Pardo}, Alba and Salvatore Castaldo and Enrico Amico and Giuseppe Pepe and Federico Marracino and Luca Capocci and Alfredo Giovannelli and Michele Madonna and {van Bergeijk}, Jeroen and Fabio Buttari and {van der Kam}, Elizabeth and Vittorio Maglione",
year = "2018",
month = "7",
day = "15",
doi = "10.1093/hmg/ddy153",
language = "English",
volume = "27",
pages = "2490--2501",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

AU - Di Pardo, Alba

AU - Castaldo, Salvatore

AU - Amico, Enrico

AU - Pepe, Giuseppe

AU - Marracino, Federico

AU - Capocci, Luca

AU - Giovannelli, Alfredo

AU - Madonna, Michele

AU - van Bergeijk, Jeroen

AU - Buttari, Fabio

AU - van der Kam, Elizabeth

AU - Maglione, Vittorio

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approachesmay open the door to newandmore targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulating sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2mice, a widely used HD animalmodel. Chronic administration of low-dose (0.1mg/kg) A-971432 slowed down the progression of the disease and significantly prolonged lifespan in symptomatic R6/2mice. Such beneficial effects were associated with activation of pro-survival pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood-brain barrier (BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432 completely protected HDmice fromthe classic progressivemotor deficit and preserved BBB integrity. Beside representing a promising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P receptor 5may be also seen as an effective approach to target brain vasculature defects in the disease.

AB - Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approachesmay open the door to newandmore targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulating sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2mice, a widely used HD animalmodel. Chronic administration of low-dose (0.1mg/kg) A-971432 slowed down the progression of the disease and significantly prolonged lifespan in symptomatic R6/2mice. Such beneficial effects were associated with activation of pro-survival pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood-brain barrier (BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432 completely protected HDmice fromthe classic progressivemotor deficit and preserved BBB integrity. Beside representing a promising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P receptor 5may be also seen as an effective approach to target brain vasculature defects in the disease.

UR - http://www.scopus.com/inward/record.url?scp=85050819926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050819926&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddy153

DO - 10.1093/hmg/ddy153

M3 - Article

C2 - 29688337

AN - SCOPUS:85050819926

VL - 27

SP - 2490

EP - 2501

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 14

ER -